Isarna Therapeutics announced the enrollment of the first patient in the BETTER Study, a parallel, two-segment Phase IIa clinical study to evaluate Isarna’s lead candidate ISTH0036 in patients with wet age-related macular degeneration (AMD) and diabetic macular edema (DME).
[Isarna Therapeutics]
6445212
nan
items
1
apa
0
default
asc
1
169734
https://www.stemcellsciencenews.com/wp-content/plugins/zotpress/